Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

They also will evaluate advances in imaging and current and emerging therapies for the treatment and management of retinal vein occlusion. Upon successful completion of this educational activity ...

In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.

Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of ...

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it received regulatory approval to ...

To Know in detail about the Retinal Vein Occlusion market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Retinal Vein Occlusion Market Forecast Some of the key facts ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

A variety of retinal signs can occur in patients who have systemic vasculitides, or who experience complications of these diseases or their treatment ... rather than the veins, and these signs ...

The EYLEA HD results were consistent across patients with branch retinal vein occlusions ... of EYLEA HD in its pivotal trials. Ocular treatment-emergent adverse events (TEAEs) occurring in ...